Sarepta Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sarepta Therapeutics (SRPT).

Price Target Range — 7 Quarters

Analyst Consensus — 24 Analysts

9Buy

10Hold

5Sell

Consensus RatingOutperform# Analysts24Avg. Consensus PT$25Upside to Avg. PT+29.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$19→$17
Oct 5, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Sell	$5
Sep 30, 2026	JP Morgan	Anupam Rama	PT Cut	Neutral	$23→$20
Sep 28, 2026	Needham	Gil Blum	Maintained	Underperform	—
Jul 9, 2026	Piper Sandler	Biren Amin	PT Cut	Neutral	$23→$20
Jul 9, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	$27
Apr 16, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Sell	$5
Mar 26, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Sell	$9→$13
Mar 26, 2026	Needham	Gil Blum	Maintained	Underperform	—
Mar 19, 2026	Oppenheimer	Kostas Biliouris	Maintained	Outperform	$37
Mar 13, 2026	Mizuho	Uy Ear	PT Raise	Outperform	$26→$31
Mar 10, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Sell	$8→$9
Mar 2, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Sell	$5
Feb 27, 2026	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$45→$38
Jan 27, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Sell	$5
Jan 23, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$32→$34
Jan 14, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Sell	$5
Dec 9, 2025	Wedbush	Yun Zhong	Initiate	Outperform	$32
Nov 5, 2025	Barclays	Gena Wang	PT Cut	Equal-Weight	$22→$20
Nov 5, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$50→$45

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and lowers the price target from $19 to $17.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.

Benzinga Newsdesk

PRO
Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) from Underperform to Underperform.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.

Benzinga Newsdesk

PRO
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.

Benzinga Newsdesk

Sarepta Therapeutics Inc

Sarepta Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17

PRO
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

PRO
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PRO
Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform

PRO
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PRO
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

People Also Watch

People Also Watch

Sarepta Therapeutics Inc

Sarepta Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17

PROHC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

PROJP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PRONeedham Reiterates Underperform on Sarepta Therapeuticsto Underperform

PROPiper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PROWolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17

PRO
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

PRO
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PRO
Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform

PRO
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PRO
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target